Bringing together the minds that are creating the future of health.

BICO partnership conference

Bringing together the minds that are creating the future of health.

BICO partnership conference

The Bio Convergence company

Bico by the numbers - Q2

Future. Forward. Fast

  • Net sales Q2 2021
    0 MUSD
  • Organic growth Q2 2021
    0 %
  • Employees
    0 +
  • Instruments in the field
    0 +
  • Publications
    0 +
  • Countries
    0 +

Trusted by
industry leaders

grey-lor
grey-johnson-johnson
grey-logo-karolinska-institutet
grey-astra_c
grey-harvard-1
grey-merck
grey-roche2
grey-amgen
grey-mit_s
grey-shiseido
grey-novaratis
grey-3M
grey-genetech
grey-bristol myers
grey-celgene
grey-takeda
grey-novo nordisk
grey-boehringer-ingelheim

Business areas

Revolutionizing Science

Our products are used in more than 2,000 laboratories including the world’s top 20 leading pharmaceutical companies, in more than 65 countries and have been cited in more than 9,000 publications.

Making the seemingly impossible, possible

Focusing on bioprinting, multiomics, cell line development and diagnostics, we enable researchers to grow cells in 3D environments, conduct high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries.

Revolutionizing Science

Our products are used in more than 2,000 laboratories including the world’s top 20 leading pharmaceutical companies, in more than 65 countries and have been cited in more than 9,000 publications.

Making the seemingly impossible, possible

Focusing on bioprinting, multiomics, cell line development and diagnostics, we enable researchers to grow cells in 3D environments, conduct high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries.
Message from the CEO

Unleashing the power of Bio Convergence

Erik Gatenholm, CEO at BICO, decided to change the group company name to better reflect the strategic bio convergence agenda and emphasize that the company comprises several subsidiaries divided into three business areas. Now, the journey begins to build a world-famous brand.

"We have always challenged and developed the industry. We will continue to do this in a new context since the new name releases even better opportunities to communicate our offering, our plans going forward, and how we contribute to create the health of the future.

Erik Gatenholm, CEO, BICO
Message from the CEO

Unleashing the power of Bio Convergence

Erik Gatenholm, CEO at BICO, decided to change the group company name to better reflect the strategic bio convergence agenda and emphasize that the company comprises several subsidiaries divided into three business areas. Now, the journey begins to build a world-famous brand.

"We have always challenged and developed the industry. We will continue to do this in a new context since the new name releases even better opportunities to communicate our offering, our plans going forward, and how we contribute to create the health of the future.

Erik Gatenholm, CEO, BICO

press releases

Calendar

November 10, 2021Q3 report 2021
February 23, 2022Year-end report 2021
March 16, 2022Annual report 2021

Contact us

    • Investor relations

    • Isabelle Ljunggren, Head of Communications
    • Email: il@bico.com
    • Sales

    • Visit our subsidiaries' websites to explore our product offering.

Press room